The DNAJC15 Knockout K-562 Polyclonal Cells offer a targeted loss-of-function model produced by CRISPR/Cas9-mediated gene disruption in a heterogeneous cell pool. This product enables functional analysis of DNAJC15 (MCJ), a mitochondrial inner membrane J-domain co-chaperone, within a suspension culture format. The knockout is achieved through genome editing without clonal selection, yielding a polyclonal population that captures diverse knockout alleles and minimizes single-clone artifacts. This approach is especially valuable for studying variable gene-dosage effects and heterogeneous cellular responses in oncogenic contexts.
K-562 cells were originally isolated from the pleural effusion of a 53-year-old female patient with chronic myelogenous leukemia in blast crisis. The cell line harbors the Philadelphia chromosome, which produces the BCR-ABL1 tyrosine kinase fusion oncogene, and expresses markers characteristic of early erythroid progenitors. Under chemical induction, K-562 cells can differentiate toward erythroid, granulocytic, or monocytic lineages, making them a versatile host for exploring the intersections between oncogenic signaling, hematopoietic differentiation, and metabolic regulation.
At the molecular level, DNAJC15 functions as an inhibitor of oxidative phosphorylation by associating with HSPA9 (mtHsp70) and components of the TIM23 translocase, including TIMM44, TIMM23, TIMM17A, and MAGMAS. This interaction restricts the assembly of respiratory supercomplexes, thereby dampening ATP synthase activity (represented by ATP5F1A) and modulating mitochondrial membrane potential and reactive oxygen species output. Upstream, DNAJC15 is silenced by DNA methylation and lies downstream of TGF-?? signaling, establishing an epigenetically controlled node. Consequently, knockout cells relieve this suppression, upregulating respiratory chain subunits such as UQCRC1 and enhancing overall mitochondrial respiration.
In the K-562 leukemia background, DNAJC15 disruption produces a metabolic rewiring that intersects with BCR-ABL-driven oncogenic pathways. BCR-ABL signaling can influence mitochondrial fitness, and the enhanced oxidative phosphorylation resulting from DNAJC15 loss provides a model to dissect how metabolic status affects differentiation propensity and drug sensitivity. The polyclonal knockout population mirrors the heterogeneous genetic landscape of malignancies, facilitating studies of clonal variation in metabolic adaptation and the emergence of chemoresistance under therapeutic pressure.
Researchers can employ these cells in a range of quantitative assays to interrogate mitochondrial function and cellular responses. Typical workflows include Seahorse metabolic flux analysis to measure oxygen consumption rates, ATP bioluminescence assays for energetic profiling, and Western blotting for OXPHOS complexes. The status of DNAJC15 epigenetic silencing can be assessed by methylation-specific PCR, while co-immunoprecipitation verifies disrupted DNAJC15?CHSPA9 interactions. Drug sensitivity studies using Annexin V/propidium iodide flow cytometry can link mitochondrial alterations to apoptotic signaling. Additionally, the cells can be combined with differentiation-inducing agents to examine lineage-specific metabolic requirements. For further information or custom services, please contact Ascent Research.
